# A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

> **NCT02031744** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 530 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** erlotinib [Tarceva]
- **DRUG:** Placebo
- **DRUG:** Onartuzumab [MetMAb]

## Key facts

- **NCT ID:** NCT02031744
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-22
- **Primary completion:** 2016-01-06
- **Final completion:** 2016-01-06
- **Target enrollment:** 530 (ESTIMATED)
- **Last updated:** 2017-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02031744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02031744, "A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02031744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*